Literature DB >> 17662614

Tumor immunoediting and immunosculpting pathways to cancer progression.

Jennifer M Reiman1, Maciej Kmieciak, Masoud H Manjili, Keith L Knutson.   

Abstract

Recent studies have suggested that a natural function of the immune system is to respond and destroy aberrant, dysfunctional cells by a process called immunosurveillance. These studies also suggest that the tumors that arise despite immunosurveillance have been immunosculpted by the immune system. The purported abilities of tumors to induce immune tolerance and suppression, the increased pathogenic behavior of the tumor cells following exposure to immune effectors and the loss of immunogenicity (i.e. immunoediting) often observed in advanced stage tumors could be the result of immunosculpting. In some cases, these immunosculpting features may be permanent and irreversible. However, in other cases, reversible epigenetic mechanisms may underlie the immune resistant tumor phenotype. Regardless, these immune-induced alterations could contribute to cancer pathogenesis. Understanding the mechanisms by which tumors evade immunity will be important for disease prevention and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662614      PMCID: PMC2742305          DOI: 10.1016/j.semcancer.2007.06.009

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  147 in total

1.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

Authors:  M J Smyth; N Y Crowe; D I Godfrey
Journal:  Int Immunol       Date:  2001-04       Impact factor: 4.823

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

Review 3.  CD4 regulatory T cells in human cancer pathogenesis.

Authors:  Keith L Knutson; Mary L Disis; Lupe G Salazar
Journal:  Cancer Immunol Immunother       Date:  2006-07-04       Impact factor: 6.968

4.  Identification of genes down-regulated during melanoma progression: a cDNA array study.

Authors:  Alfonso Baldi; Tullio Battista; Antonio De Luca; Daniele Santini; Luigi Rossiello; Feliciano Baldi; Pier Giorgio Natali; Daniela Lombardi; Mauro Picardo; Armando Felsani; Marco G Paggi
Journal:  Exp Dermatol       Date:  2003-04       Impact factor: 3.960

Review 5.  Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models.

Authors:  Darren N Seril; Jie Liao; Guang-Yu Yang; Chung S Yang
Journal:  Carcinogenesis       Date:  2003-03       Impact factor: 4.944

Review 6.  Immunosuppressive drugs and cancer.

Authors:  Thierry Vial; Jacques Descotes
Journal:  Toxicology       Date:  2003-04-01       Impact factor: 4.221

7.  Haplotype-independent costimulation of IL-10 secretion by SDF-1/CXCL12 proceeds via AP-1 binding to the human IL-10 promoter.

Authors:  Kimberly N Kremer; Ashok Kumar; Karen E Hedin
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

8.  Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.

Authors:  C M Cabrera; P Jiménez; T Cabrera; C Esparza; F Ruiz-Cabello; F Garrido
Journal:  Tissue Antigens       Date:  2003-03

9.  Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

Authors:  Lisa H Butterfield; Antoni Ribas; Vivian B Dissette; Saral N Amarnani; Huong T Vu; Denise Oseguera; He-Jing Wang; Robert M Elashoff; William H McBride; Bijay Mukherji; Alistair J Cochran; John A Glaspy; James S Economou
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  61 in total

1.  Prognostic significance of HLA class I expressing in gastric carcinoma defined by monoclonal anti-pan HLA class I antibody, EMR8-5.

Authors:  Hae-Wan Lee; Soo Kee Min; Young-Su Ju; Joohon Sung; Man Sup Lim; Dae Hyun Yang; Bong Hwa Lee
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

Review 2.  Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases.

Authors:  Paola Nisticò; Mina J Bissell; Derek C Radisky
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

3.  The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.

Authors:  Qiu-Xia Qu; Qin Huang; Yu Shen; Yi-Bei Zhu; Xue-Guang Zhang
Journal:  Tumour Biol       Date:  2015-11-06

4.  Log odds of positive lymph nodes in colon cancer: a meaningful ratio-based lymph node classification system.

Authors:  Roberto Persiani; Ferdinando C M Cananzi; Alberto Biondi; Giuseppe Paliani; Andrea Tufo; Francesco Ferrara; Vincenzo Vigorita; Domenico D'Ugo
Journal:  World J Surg       Date:  2012-03       Impact factor: 3.352

5.  Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.

Authors:  Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Mayumi Kawabe; Nina Chi; Laima Spokas; Devin B Lowe; Christina Goldbach; Sean Alber; Simon C Watkins; Lisa H Butterfield; Pawel Kalinski; John M Kirkwood; Walter J Storkus
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

6.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

Review 7.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 8.  Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.

Authors:  Julia Kravchenko; Emanuela Corsini; Marc A Williams; William Decker; Masoud H Manjili; Takemi Otsuki; Neetu Singh; Faha Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson; Leroy Lowe; H Kim Lyerly
Journal:  Carcinogenesis       Date:  2015-05-22       Impact factor: 4.944

Review 9.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 10.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.